Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Data analysis: The superiority of lab data in rare disease patient identification

Data analysis

A major challenge in managing IgA nephropathy (IgAN) is delayed diagnosis. While claims data flags these patients with a broad chronic kidney disease (CKD) diagnosis, it creates critical blind spots.

 

This comparative analysis demonstrates how integrating real-world lab data provides the specific clinical details required to suspect IgAN and prompt further diagnostic steps.

 

See how real-world lab data can provide clinical signals indicating IgAN an average of 2.5 years sooner than the formal diagnosis appears on a claim.

Data analysis: The superiority of lab data in rare disease patient identification

See the value of
real-world lab data in rare disease patient identification

941

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.